Pre-clinical research on adverse effects in CAR T-cell therapy

Rationale for indication

• CAR T-cell therapy has emerged as an effective treatment for leukemia and is a very rapidly expanding area in oncology.
• Cytokine release syndrome (CSR) is a common side effect, seen in between 50-100% of the patients, which leads to systematic inflammation or even death.
• Our new products have the ability to attenuate these undesired immune reactions.

Commercial potential

• The CAR T-cell therapy market size was valued at $2.6 billion in 2022 and is estimated to reach $35.9 billion by 2032, exhibiting a CAGR of 28,5% from 2023 to 2032.
• The growth of the CAR T-cell therapy market is driven by:
• Development of the new CAR T-cell therapy, and high effectivity of CAR T-cell therapy over other conventional drugs for cancer treatment.